Wall Street analysts expect Invitae Co. (NYSE:NVTA – Get Rating) to report sales of $126.72 million for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Invitae’s earnings. The highest sales estimate is $127.95 million and the lowest is $125.30 million. Invitae reported sales of $103.62 million in the same quarter […]
Brokerages expect Invitae Co. (NYSE:NVTA – Get Rating) to report sales of $130.38 million for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Invitae’s earnings, with estimates ranging from $125.30 million to $138.81 million. Invitae posted sales of $103.62 million during the same quarter last year, which suggests a […]
Strs Ohio cut its holdings in Invitae Co. (NYSE:NVTA – Get Rating) by 80.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 4,500 shares of the medical research company’s stock after selling 18,900 shares during the period. Strs Ohio’s holdings in Invitae were worth $68,000 as of its most recent SEC filing. […]
Shares of Invitae Co. (NYSE:NVTA – Get Rating) have earned a consensus recommendation of “Hold” from the seven brokerages that are covering the company, Marketbeat reports. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year target price among analysts […]
Invitae Co. (NYSE:NVTA – Get Rating) General Counsel Thomas Brida sold 17,987 shares of the business’s stock in a transaction on Monday, March 14th. The stock was sold at an average price of $6.69, for a total transaction of $120,333.03. The sale was disclosed in a filing with the Securities & Exchange Commission, which is […]